Kiniksa Pharmaceuticals International (KNSA) Capital Expenditures Growth (1y) (2018 - 2026)
Kiniksa Pharmaceuticals International (KNSA) Capital Expenditures Growth (1y) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.24 Bn | 87.37 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.95 Bn | 32.21 Bn | 1.97 Bn | 32.28% |
| 3 | Zoetis | 32.51 Bn | 30.56 Bn | 1.62 Bn | -38.20% |
| 4 | Takeda Pharmaceutical | 27.58 Bn | 23.52 Bn | 4.39 Bn | -15.72% |
| 5 | United Therapeutics | 23.18 Bn | 21.02 Bn | 648.10 Mn | 32.98% |
| 6 | RedHill Biopharma | 20.53 Bn | 20.53 Bn | - | - |
| 7 | Viatris | 20.26 Bn | 18.46 Bn | 1.16 Bn | -6.34% |
| 8 | Neurocrine Biosciences | 17.94 Bn | 16.63 Bn | 800.70 Mn | -86.92% |
| 9 | Elanco Animal Health | 12.73 Bn | 12.30 Bn | 785.00 Mn | -21.54% |
| 10 | Kiniksa Pharmaceuticals International | 4.93 Bn | 4.47 Bn | 193.47 Mn | 217.65% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 217.65% |
| Dec 31, 2025 | -97.12% |
| Sep 30, 2025 | 12,552.17% |
| Jun 30, 2025 | -2,743.42% |
| Mar 31, 2025 | -66.67% |
| Dec 31, 2024 | 304.68% |
| Sep 30, 2024 | 43.75% |
| Jun 30, 2024 | -97.71% |
| Mar 31, 2024 | 103.12% |
| Dec 31, 2023 | -14,456.25% |
| Sep 30, 2023 | -27.27% |
| Jun 30, 2023 | 15.89% |
| Mar 31, 2023 | -18.62% |
| Dec 31, 2022 | -101.03% |
| Sep 30, 2022 | 119.13% |
| Jun 30, 2022 | 1,175.56% |
| Mar 31, 2022 | -5,201.85% |
| Dec 31, 2021 | 5,572.73% |
| Sep 30, 2021 | -2,400.00% |
| Mar 31, 2021 | -75.78% |